Tag: Gensight
GenSight Biologics: recruiting for the launch of Lumevoq
(CercleFinance.com) – GenSight Biologics strengthens its management team to support the launch of Lumevoq in Europe. Philippe Motté is appointed Senior Vice-President, Regulatory Affairs and Quality, reporting to Bernard Gilly,…
GenSight: Stock climbs after favorable follow-up study
(CercleFinance.com) – GenSight Biologics shares soared more than 20% on Wednesday morning on the Paris Stock Exchange after the biopharmaceutical company reported data collected over five years for its treatment…
Gensight: few reactions
(Boursier.com) — Gensight fell 0.8% to 2.22 euros on Friday, while the company’s operating income increased by 3.6% to 7.7 million euros in 2021, compared to 7.4 million euros in…
GenSight: towards a presentation at the NANOS congress – 02/14/2022 at 13:40
(CercleFinance.com) – GenSight Biologics announces that the results of the REFLECT phase III clinical study of its Lumevoq gene therapy will be presented at the Annual Meeting of the North…
GenSight: Stock Advances After Tracking Data – 01/24/2022 11:33 AM
(CercleFinance.com) – GenSight Biologics rose more than 2% on Monday on the Paris Stock Exchange following the publication of encouraging follow-up data concerning its Lumevoq gene therapy. According to the…
Gensight biologics: Taking the plunge with an FDA request
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…